证券代码：300294 证券简称：博雅生物 公告编号：2023-031 华润博雅生物制药集团股份有限公司 第七届监事会第十九次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 详见中国证监会指定的创业板信息披露网站巨潮资讯网的《2023 年半年度 报告全文》《2023 年半年度报告摘要》。 （二）审议通过《关于 2023 年半年度募集资金存放与使用情况的专项报告 的议案》 表决结果：3 票同意、0 票反对、0 票弃权 公司监事会认为：公司严格按照《上市公司规范运作》和《公司募集资金管 理制度》等相关规定管理募集资金专项账户，募集资金存放与使用合法合规；公 司《2023 年半年度募集资金存放与使用情况的专项报告》内容真实、准确、完 华润博雅生物制药集团股份有限公司（以下简称"公司"）第七届监事会第 十九次会议于 2023 年 8 月 11 日以邮件及通讯方式通知，并于 2023 年 8 月 21 日在公司二楼会议室以现场加通讯表决方式召开。会议应参加表决监事 3 人，实 参加表决监事 3 人。会议由监事主席唐娜女士主持，公司部分高级 ...

华润博雅生物制药集团股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用 | 占用方与上 | 上市公司 | 2023 年期初 | | 2023 | 年半年度占 | 2023 | 年半年 | 2023 | 年半年 | 2023 | 年半年 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 方名称 | 市公司的关 | 核算的会 | 占用资金余额 | | | 用累计发生金额 | | 度占用资金的 | 度偿还累计 | | 度期末占用 | | 原因 | 占用性质 | | | | 联关系 | 计科目 | | | | （不含利息） | | 利息（如有） | 发生金额 | | 资金余额 | | | | | 控股股东、实际控制人及其 | | | | | | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | | | | | | 小计 ...

证券代码：300294 证券简称：博雅生物 公告编号：2023-034 华润博雅生物制药集团股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运 作》（以下简称"上市公司规范运作"）《深圳证券交易所创业板股票上市规 则》（以下简称"股票上市规则"）《深圳证券交易所创业板上市公司自律监 管指南第2号——公告格式》相关格式指引的规定及要求，华润博雅生物制药集 团股份有限公司（以下简称"公司"或"华润博雅生物"）编制了截至2023年6 月30日的"2023年半年度募集资金存放与使用情况的专项报告"。具体情况如 下： 一、2018 年非公开发行募集资金基本情况 （一）募集资金金额和实际到账时间 根据公司2017年第二次临时股东大会会议决议及中国证券监督管理委员会 《关于核准博雅生物制药集团股份有限公司非公开发行股票的批复》（证监许 可[2018]117号），核准公司非公开 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《关于在上市公司建立独立董事制度的指导意见》及《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》（以下简称"《上市公司规范运作》"）《华润博雅生物制药集团 股份有限公司独立董事工作制度》等相关法律法规和规范性文件规定，作为华润 博雅生物制药集团股份有限公司（以下简称"公司"）的独立董事，本着认真、 负责的态度，基于独立、审慎、客观的立场，独立董事对公司第七届董事会第二 十二次会议审议的相关事项进行了认真审核，并发表如下独立意见： 华润博雅生物制药集团股份有限公司独立董事 对公司第七届董事会第二十二次会议相关事项的独立意见 一、关于公司控股股东及其关联方资金占用和对外担保的独立意见 1、报告期内（2023 年 1 月 1 日至 2023 年 6 月 30 日），公司不存在控股股 东及其他关联方违规占用及变相占用公司资金的情况。 2、报告期内（2023 年 1 月 1 日至 2023 年 6 月 30 日），公司不存在为控股 股东及其他关联方、任何非法人单位或个人违规提供担保的 ...

证券代码：300294 证券简称：博雅生物 公告编号：2023-030 详见中国证监会指定的创业板信息披露网站巨潮资讯网的《2023 年半年度 报告全文》《2023 年半年度报告摘要》。 （二）审议通过《关于公司<2023 年半年度募集资金存放与使用情况的专项 报告>的议案》 表决结果：9 票同意、0 票反对、0 票弃权 华润博雅生物制药集团股份有限公司 第七届董事会第二十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 华润博雅生物制药集团股份有限公司（以下简称"公司"）第七届董事会第 二十二次会议于 2023 年 8 月 11 日以邮件及通讯方式通知，并于 2023 年 8 月 21 日在公司二楼会议室以现场加通讯表决方式召开。会议应参加表决董事 9 人，实 参加表决董事 9 人。会议由董事长陶然先生主持，公司监事及高级管理人员列席 了会议。本次会议符合《中华人民共和国公司法》《中华人民共和国证券法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称" ...

Financial Performance - The company's revenue for Q1 2023 was CNY 805,928,136.64, representing a 23.11% increase compared to CNY 654,635,799.08 in the same period last year[19] - The net profit attributable to shareholders for Q1 2023 was CNY 170,317,490.97, a 64.47% increase from CNY 103,554,147.18 year-on-year[19] - The total profit amounted to 205,802,789.13, an increase from 125,762,971.64[45] - Net profit reached 174,373,215.65, compared to 106,852,356.15 in the previous period, reflecting a significant growth[45] - The net profit attributable to the parent company's owners was 170,317,490.97, up from 103,554,147.18[45] - The overall financial performance indicates a robust growth trajectory and improved profitability metrics[45] Cash Flow - The net cash flow from operating activities surged to CNY 222,678,836.22, marking a significant increase of 905.46% compared to CNY 22,146,972.56 in the previous year[19] - Cash received from sales and services increased by 30.39% to 782,399,226.54, primarily due to increased collections[32] - Cash paid for purchasing goods and services rose by 32.06% to 295,808,934.54, mainly due to increased procurement of medical supplies[32] - Investment activities generated a net cash outflow of ¥20,268,839.68, an improvement from a net outflow of ¥712,158,654.56 in the previous period[41] - The company reported a net increase in cash and cash equivalents of ¥179,436,811.37, contrasting with a decrease of ¥690,691,299.91 in the previous period[41] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 8,196,383,781.60, reflecting a 2.03% increase from CNY 8,033,175,408.45 at the end of the previous year[19] - The total current assets reached CNY 6,239,082,168.98, an increase from CNY 6,073,386,246.99 at the beginning of the year[15] - Total liabilities rose to ¥771,236,715.69 from ¥748,348,858.19 in the previous period, reflecting ongoing financial commitments[43] - The total equity attributable to shareholders increased to ¥7,355,951,977.81, up from ¥7,185,634,486.84 in the previous period, indicating growth in shareholder value[43] Earnings and Expenses - The basic earnings per share for Q1 2023 was CNY 0.34, a 61.90% increase from CNY 0.21 in the same period last year[19] - The diluted earnings per share also stood at CNY 0.34, reflecting the same growth rate of 61.90% compared to CNY 0.21 year-on-year[19] - Operating costs increased by 42.64% to 424,061,104.31, attributed to revenue growth and changes in sales structure[23] - R&D expenses rose by 45.32% to 9,984,394.66, driven by increased investment in blood product research[23] - Income tax expenses were 31,429,573.48, up from 18,910,615.49, indicating higher tax obligations[45] Other Financial Metrics - The company reported a significant increase in non-recurring gains and losses amounting to CNY 32,502,159.86 after tax for the current period[22] - Accounts receivable decreased by 100.00% to 0.00, primarily due to the expiration of commercial acceptance bills[23] - Prepayments decreased by 33.84% to 6,389,963.81, mainly due to the write-off of prepayments for goods received[23] - Fair value changes in investment income surged by 518.81% to 34,757,152.48, resulting from changes in the fair value of financial products and merger fund investments[23] - The company reported a significant increase in net profit from continuing operations, maintaining a strong performance[45]

Financial Performance - The company’s operating revenue for 2022 was ¥2,758,701,315.10, representing a 4.08% increase compared to ¥2,650,528,421.87 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥432,197,553.97, a 25.45% increase from ¥344,528,999.52 in 2021[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥392,124,538.69, up 33.61% from ¥293,492,852.21 in 2021[17]. - The company's cash flow from operating activities decreased by 55.67% to ¥596,437,198.85 in 2022, down from ¥1,345,377,085.21 in 2021[17]. - The total assets at the end of 2022 were ¥8,033,175,408.45, a 5.40% increase from ¥7,621,775,902.48 at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were ¥7,185,634,486.84, reflecting a 5.22% increase from ¥6,829,074,243.57 at the end of 2021[17]. - The company achieved total operating revenue of ¥2,758,701,315.10, a year-on-year increase of 4.08%[45]. - The operating profit reached ¥532,180,673.01, reflecting a growth of 20.12% compared to the previous year[45]. - The blood products business generated operating revenue of ¥1,342,217,158.74, up 8.96% from ¥1,231,862,874.38 in 2021[46]. - The diabetes business saw a decline in operating revenue to ¥178,390,600.88, down 25.01% due to the impact of centralized procurement policies[46]. - The biopharmaceutical business reported operating revenue of ¥438,116,868.80, a decrease of 14.25% influenced by product exits from medical insurance[47]. - The pharmaceutical distribution business (Fuda Pharmaceutical) achieved operating revenue of ¥814,214,548.78, an increase of 22.69% driven by increased sales of immunoglobulin products[47]. Dividend Distribution - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 504,248,738 shares[4]. - The company plans to distribute a cash dividend of 1.5 yuan per 10 shares, totaling 75,637,310.70 yuan (including tax) based on a share base of 504,248,738 shares[162]. - The total cash dividend amount for the year is 100,849,747.60 yuan (including tax), which accounts for 100% of the total profit distribution[164]. - The company reported a distributable profit of 2,086,809,493.36 yuan for the year[164]. - The company has not proposed any stock bonus distribution for the reporting period[165]. Market and Product Development - The company reported a total of 9 product varieties in the blood products sector, with a significant market demand exceeding the current supply[26]. - The domestic market for blood products reached ¥43 billion in 2021, with a year-on-year growth of 11.17%[28]. - The estimated demand for raw plasma in China has exceeded 16,000 tons per year, while the actual collection was approximately 10,181 tons in 2022, indicating a supply shortfall[28]. - The company focuses on blood products, including albumin, immunoglobulin, and coagulation factors, and is one of the leading domestic producers in this sector, offering 9 product varieties in 23 specifications[33]. - The company aims to become a world-class blood product enterprise while stabilizing its non-blood product business, emphasizing the importance of blood products in its overall strategy[33]. - The company has increased R&D investment to enhance its product pipeline, being one of the few in the industry with a complete range of three types of products[29]. - The company has optimized its product structure with the recent launch of PCC and factor VIII, improving its core product yield above the industry average[29]. - The company has achieved a balance between production and sales for its core products, enhancing its market penetration and coverage through academic system development[29]. - The company aims to expand its market presence and enhance product competitiveness through new strategies and product development[35]. - The company launched new products, including the production approval of coagulation factor VIII, enhancing its product portfolio[50]. Research and Development - The company has a strong R&D capability, having undertaken over 20 government projects and holding more than 200 patents, with ongoing projects aimed at expanding its blood product offerings[58]. - The number of R&D personnel increased to 220 in 2022, a growth of 2.33% compared to 215 in 2021[78]. - R&D expenditure amounted to ¥77,174,985.45 in 2022, representing 2.80% of operating revenue, down from 3.39% in 2021[78]. - The company is currently conducting clinical research on several products, including the von Willebrand factor and intravenous immunoglobulin, with significant development expenditures reported[78]. - The company has committed to returning all temporarily used idle funds to the dedicated fundraising account by the end of the specified period[100]. Operational Challenges and Strategies - The company experienced a significant decline in cash flow from operating activities, which may impact future investment and operational strategies[17]. - The company faces risks in new product development due to long cycles and high costs; it will conduct comprehensive market research and strengthen project management to ensure timely product launches[117]. - The company is adapting to increasing regulatory pressures in the pharmaceutical industry by optimizing production capacity and enhancing product pipelines to counter potential price declines[119]. - The company is committed to enhancing its operational management capabilities at plasma stations, focusing on cost control and quality management to increase plasma collection volume[109]. - The company plans to implement a series of operational optimization measures to achieve steady growth in revenue and net profit in 2023[112]. Environmental Compliance - The company has successfully passed environmental protection inspections and complies with national emission standards, ensuring no pollution to surrounding environments[175]. - The company’s COD discharge is 83.518 mg/L, well below the industry standard of 220 mg/L, with a total discharge of 4.227 tons[178]. - The company reported a total nitrogen level of 5.898 mg/L at the North Corner facility, which is below the regulatory limit of 40 mg/L[179]. - The company achieved a liquid waste discharge of 3.8905 tons, adhering to the wastewater discharge standards[179]. - The company has implemented online monitoring for wastewater parameters to ensure compliance with environmental standards[179]. Corporate Governance - The company has established a fair, transparent, and effective performance evaluation and incentive mechanism for senior management, aiming to attract and retain outstanding talent[129]. - The company maintains complete independence in business, personnel, assets, organization, and finance from its controlling shareholders, ensuring independent operations[131][132][133][134][135]. - The company has a dedicated board secretary responsible for information disclosure, ensuring timely and accurate communication with shareholders[129]. - The company has set up three specialized committees under the board of directors to enhance operational efficiency[129]. - The company held its annual general meeting with a participation ratio of 42.97% on April 12, 2022, and a temporary shareholders' meeting with a participation ratio of 46.31% on January 28, 2022[137].

Financial Performance - The company's operating revenue for the third quarter was ¥684,026,058.95, a decrease of 4.55% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥139,440,739.05, an increase of 10.89% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥108,414,674.24, down 12.90% from the previous year[5]. - The basic earnings per share for the quarter was ¥0.2800, a decrease of 6.67% compared to the same period last year[5]. - The total profit amounted to CNY 504,028,174.17, compared to CNY 394,684,389.63 in the previous period, reflecting an increase of about 27.7%[36]. - The operating profit reached CNY 505,255,213.36, up from CNY 392,621,590.85, indicating a growth of approximately 28.7%[36]. - The net profit attributable to shareholders of the parent company was CNY 418,279,088.07, an increase from CNY 323,458,914.31 in the previous period, representing a growth of approximately 29.3%[37]. - The total comprehensive income amounted to CNY 428,899,020.70, compared to CNY 349,903,789.47 in the previous period, reflecting an increase of approximately 22.5%[37]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,979,553,465.16, reflecting a 4.69% increase from the end of the previous year[5]. - The equity attributable to shareholders increased to ¥7,171,716,020.94, up 5.02% from the previous year[5]. - The company's total liabilities as of September 30, 2022, were CNY 711,315,701.71, compared to CNY 701,299,849.03 at the beginning of the year[30]. - The company's total current assets reached CNY 5,991,275,687.02, up from CNY 5,645,912,964.89 at the beginning of the year[25]. Cash Flow - The cash flow from operating activities showed a significant decline of 67.87% year-on-year, totaling ¥377,007,297.33[5]. - The cash flow from operating activities was CNY 377,007,297.33, down from CNY 1,173,508,351.28 in the previous period, showing a decline of approximately 67.9%[42]. - Cash inflow from investment activities totaled CNY 3,448,467,134.16, significantly higher than CNY 578,069,667.36 in the previous period, marking an increase of about 497.5%[42]. - The net cash flow from investment activities was negative at CNY -778,543,985.54, slightly improved from CNY -788,695,949.14 in the previous period[45]. Investments and Expenses - The company's cash and cash equivalents decreased by 30.60% to ¥1,099,155,602.26 due to investments in financial products[10]. - The company's intangible assets increased by 57.35% to ¥266,665,134.59, primarily due to the transfer of R&D projects[10]. - R&D expenses decreased by 31.85% to ¥35,626,723.74, primarily due to the capitalization of certain projects[13]. - Investment income increased by 587.91% to ¥48,175,581.16, mainly driven by higher returns from financial products[13]. - Cash paid for investments surged by 216.32% to ¥4,150,000,000.00, primarily due to increased purchases of financial products[13]. - The company reported a significant increase in financial expenses by 606.60% to -¥18,322,375.98, due to increased interest income from bank deposits[13]. Strategic Developments - The company established a new subsidiary, Yangcheng Plasma Station, holding an 80% stake, to enhance strategic cooperation in the blood products sector[19]. - The company obtained the drug registration certificate for human coagulation factor VIII in August 2022, enhancing its product line and increasing the value of plasma utilization per ton[20]. - The company's subsidiary, Tianan Pharmaceutical, received the drug registration certificate for acarbose tablets in September 2022, which will strengthen its diabetes medication product line and market competitiveness[21]. - The company is focused on expanding its product offerings and enhancing its market position through strategic product registrations and certifications[20][21]. Other Information - Deferred tax assets rose by 37.23% to ¥37,655,335.12, mainly due to changes in the fair value of financial products[13]. - Long-term borrowings decreased by 100% as they were reclassified to current liabilities[13]. - Other non-current assets increased by 41.14% to ¥52,503,771.62, primarily due to land deposit payments[13]. - Contract liabilities increased by 39.25% to ¥18,067,719.38, reflecting an increase in advance payments received[13]. - The third quarter report has not been audited[46]. - The board of directors of China Resources BoYa Bio-Pharmaceutical Group Co., Ltd. held a meeting on October 24, 2022[47].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-on-year growth of 15%[1] - The company's operating revenue for the first half of 2022 was approximately RMB 1.40 billion, representing an increase of 8.02% compared to the same period last year[30] - The net profit attributable to shareholders of the listed company reached approximately RMB 278.84 million, a significant increase of 41.03% year-on-year[30] - The net profit after deducting non-recurring gains and losses was approximately RMB 247.57 million, up 27.28% from the previous year[30] - The basic earnings per share increased to RMB 0.55, reflecting a growth of 19.57% compared to RMB 0.46 in the same period last year[30] - The company achieved total revenue of ¥1,398,718,256.57, an increase of 8.02% year-on-year[70] - The net profit attributable to shareholders was ¥278,838,349.02, reflecting a growth of 41.03% compared to the previous year[70] - Blood products revenue reached ¥692,886,681.76, up 17.01% year-on-year, driven by new product sales starting in April 2021[70] - The diabetes drug segment, operated by Tianan Pharmaceutical, saw a revenue decline of 11.74% to ¥101,198,506.54, primarily due to national procurement policies[70] - The biochemical drug segment, managed by Xinbai Pharmaceutical, experienced a revenue drop of 16.87% to ¥208,451,399.28, attributed to intensified market competition and regional procurement policies[73] Product Development and Market Expansion - New product development includes the launch of two innovative blood products, expected to receive regulatory approval by Q4 2022, which could potentially increase market share by 5%[4] - The company plans to expand its market presence by establishing three new plasma collection stations in key regions, aiming to increase raw material supply by 30%[5] - A strategic acquisition of a competitor is in progress, which is projected to enhance the company's production capacity by 25%[6] - The company aims to become a world-class blood product enterprise, focusing on blood products while stabilizing non-blood product businesses[40] - The company is focusing on expanding its blood products pipeline, with ongoing projects including human coagulation factor VIII and high-concentration immunoglobulin[64] - The company plans to enhance its marketing capabilities and optimize product structure to mitigate the impact of procurement policies on its non-blood products[67] Research and Development - The company has allocated 100 million RMB for R&D in new technologies aimed at improving product quality and production efficiency[7] - The company maintains a dual approach to research and development, combining independent and collaborative efforts with universities and research institutions[55] - The company has established a peptide drug engineering technology research center to strengthen its competitive advantage in biochemical drugs[67] - R&D investment decreased by 43.39% to ¥34,638,320.79 due to lower investment in ongoing product stages[93] - The company aims to enhance R&D investment and collaboration with universities and research institutions to secure product registration certificates for new products[134] Financial Management and Investment - The company does not plan to distribute cash dividends or issue bonus shares for the current fiscal year, focusing instead on reinvestment for growth[9] - The company reported a net decrease in cash and cash equivalents of ¥574,700,096.12, a 1,514.68% decline, attributed to the same recovery of prepayments[93] - The total investment amount during the reporting period was CNY 4,174,967,923.96, representing a 210.51% increase compared to CNY 1,344,552,620.86 in the same period last year[109] - The company plans to allocate all unused raised funds amounting to CNY 99,607.51 million to the "Intelligent Factory for Blood Products (Phase I) Construction Project"[115] - The company has a total of RMB 415,000 million in entrusted financial management, with RMB 345,000 million remaining due and no overdue amounts reported[122] Operational Challenges and Risks - Risks associated with raw material supply shortages were emphasized, particularly the reliance on healthy human plasma, which is currently under tight supply conditions[10] - The company faces risks related to the supply of raw materials, specifically human plasma, which is critical for blood product production, and the supply is currently tight due to regulatory constraints[129] - The company will optimize production capacity and enhance product lines to cope with potential price declines due to national medical policies[136] - The company faces goodwill impairment risks due to the merger with Tianan Pharmaceutical, Xinbai Pharmaceutical, and Fuda Pharmaceutical, which may adversely affect its financial performance[136] Environmental Compliance and Social Responsibility - The company has implemented a comprehensive environmental monitoring system to ensure real-time tracking of volatile organic compounds and energy consumption of environmental facilities[162] - The companies have reported no administrative penalties due to environmental issues during the reporting period[173] - The company has donated nearly 2 million RMB to various social welfare projects, including health initiatives and educational support[185] - The company emphasizes social responsibility, focusing on creating social value while enhancing corporate value[179] - The company has established a "sunshine procurement" policy to enhance supplier management and maintain long-term cooperative relationships[184] Employee Engagement and Training - The company has implemented a "3+1 talent training plan" and achieved a 100% employee training coverage rate with an average training investment of over 700 RMB per employee[181]

Financial Performance - The company's revenue for Q1 2022 was ¥654,635,799.08, a decrease of 4.89% compared to the adjusted revenue of ¥672,101,665.87 in the same period last year[5] - Net profit attributable to shareholders for Q1 2022 was ¥103,554,147.18, representing a 2.80% increase from the adjusted net profit of ¥100,736,164.66 in the previous year[5] - Basic and diluted earnings per share for Q1 2022 were both ¥0.21, down 12.50% from ¥0.24 in the previous year[5] - Total operating revenue for the current period reached ¥654,635,799.08, an increase of 4.1% compared to ¥624,118,627.05 in the previous period[35] - Net profit for the current period was ¥106,852,356.15, compared to ¥103,957,040.08 in the previous period, marking an increase of 2.8%[38] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 86.10%, amounting to ¥22,146,972.56 compared to ¥159,306,575.70 in the same period last year[5] - The company reported a net cash flow from investing activities of -712,158,654.56, compared to -23,839,711.56 in the previous period, indicating a significant increase in investment outflows[46] - The net increase in cash and cash equivalents was -690,691,299.91, compared to -78,882,618.94 in the previous period, showing a substantial decline in cash reserves[46] - The ending balance of cash and cash equivalents was 888,570,197.44, down from 1,579,261,497.35 at the beginning of the period[46] - Cash paid for dividends and interest decreased by 98.37% due to reduced interest expenses[14] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥7,679,391,433.49, reflecting a 0.76% increase from ¥7,621,775,902.48 at the end of the previous year[5] - The total liabilities of the company were RMB 652,063,023.89, down from RMB 701,299,849.03, showing a reduction in liabilities[31] - The company's non-current assets totaled RMB 1,959,146,016.98, a decrease from RMB 1,975,862,937.59[31] - Accounts receivable decreased by 100% due to the cancellation of commercial acceptance settlements in 2022 and the maturity of commercial acceptances in 2021[14] Investments and Expenditures - The company plans to invest RMB 996,075,100.00 in the construction of a blood product intelligent factory, reallocating unused funds from a previous project[24] - Cash paid for purchasing goods and receiving services increased by 57.02% primarily due to increased procurement[14] - Cash paid for investment increased by 726.54% mainly due to the purchase of financial products[14] - The company made significant investments totaling 700,000,000.00, indicating a focus on growth and expansion[46] Changes in Equity and Financial Management - The equity attributable to shareholders increased by 1.52% to ¥6,932,628,390.75 from ¥6,829,074,243.57 at the end of the previous year[5] - The weighted average return on equity decreased by 0.92 percentage points to 1.50% from 2.42% in the previous year[5] - The company recorded a financial expense of -¥6,202,545.54, compared to -¥784,174.50 in the previous period, indicating improved financial management[35] Operational Adjustments and Strategic Focus - The company has made adjustments to its accounting policies, affecting revenue recognition for certain cooperative production agreements[8] - The company is focusing on expanding its market presence through the development of new products and technologies[24] - The company is focusing on strategic investments and may be exploring new technologies and market expansions based on the significant cash outflows for investments[46] Other Financial Metrics - Research and development expenses were ¥6,870,470.10, down from ¥8,165,544.65, reflecting a decrease of 15.8%[35] - Other income for the current period was ¥1,702,903.79, up from ¥1,081,046.33, representing an increase of 57.5%[38] - The report for the first quarter was not audited, which may affect the reliability of the financial data presented[47]